ES2397548T5 - Glicoproteína inmunorreactiva gp19 de Ehrlichia canis - Google Patents

Glicoproteína inmunorreactiva gp19 de Ehrlichia canis Download PDF

Info

Publication number
ES2397548T5
ES2397548T5 ES07873953T ES07873953T ES2397548T5 ES 2397548 T5 ES2397548 T5 ES 2397548T5 ES 07873953 T ES07873953 T ES 07873953T ES 07873953 T ES07873953 T ES 07873953T ES 2397548 T5 ES2397548 T5 ES 2397548T5
Authority
ES
Spain
Prior art keywords
seq
antibody
canis
polypeptide
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07873953T
Other languages
English (en)
Spanish (es)
Other versions
ES2397548T3 (es
Inventor
Jere Mcbride
Christopher Doyle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Development Foundation
Original Assignee
Research Development Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39596493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2397548(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Research Development Foundation filed Critical Research Development Foundation
Publication of ES2397548T3 publication Critical patent/ES2397548T3/es
Application granted granted Critical
Publication of ES2397548T5 publication Critical patent/ES2397548T5/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0233—Rickettsiales, e.g. Anaplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1246—Rickettsiales (O)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/29—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Richettsiales (o)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES07873953T 2006-08-31 2007-08-07 Glicoproteína inmunorreactiva gp19 de Ehrlichia canis Active ES2397548T5 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84146506P 2006-08-31 2006-08-31
US841465P 2006-08-31
PCT/US2007/075343 WO2008112007A1 (en) 2006-08-31 2007-08-07 Immunoreactive glycoprotein gp19 of ehrlichia canis

Publications (2)

Publication Number Publication Date
ES2397548T3 ES2397548T3 (es) 2013-03-07
ES2397548T5 true ES2397548T5 (es) 2021-05-06

Family

ID=39596493

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07873953T Active ES2397548T5 (es) 2006-08-31 2007-08-07 Glicoproteína inmunorreactiva gp19 de Ehrlichia canis

Country Status (7)

Country Link
US (3) US9605032B2 (enExample)
EP (1) EP2064231B2 (enExample)
JP (2) JP5498164B2 (enExample)
AU (1) AU2007348944B2 (enExample)
CA (1) CA2662246C (enExample)
ES (1) ES2397548T5 (enExample)
WO (1) WO2008112007A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3527582B1 (en) 2005-04-04 2022-08-17 IDEXX Laboratories, Inc. Ehrlichia canis diva (differentiate infected from vaccinated animals)
US7842474B2 (en) 2005-04-04 2010-11-30 Idexx Laboratories, Inc. Ehrlichia canis DIVA (differentiate infected from vaccinated animals)
EP2064231B2 (en) * 2006-08-31 2020-08-26 Research Development Foundation Immunoreactive glycoprotein gp19 of ehrlichia canis
WO2008137881A2 (en) 2007-05-04 2008-11-13 The Ohio State University Research Foundation Ehrlichia ewingii proteins, nucleic acids, and methods of their use
US7964366B2 (en) * 2007-09-21 2011-06-21 Idexx Laboratories, Inc. Methods and compositions for detection of Ehrlichia chaffeensis (VLPT)
JP5759724B2 (ja) 2007-10-31 2015-08-05 アイデックス ラボラトリーズ インコーポレイテッド エーリキア・カニス（Ｅｈｒｌｉｃｈｉａｃａｎｉｓ）のＤＩＶＡ（ワクチン接種した動物から感染した動物を区別する）
GB2467529B (en) 2009-01-30 2013-03-06 Hughes Safety Showers Ltd Frame for a shelter
CA2796563C (en) 2009-04-28 2018-05-22 Research Development Foundation Immunoreactive ehrlichia p120/p140 epitopes and uses thereof
US20140162256A1 (en) 2011-03-31 2014-06-12 Yasuko Rikihisa Compositions and methods for the detection of anaplasma platys
EP2925352B1 (en) * 2012-12-03 2019-10-02 Ohio State Innovation Foundation Ehrlichial invasin for immunization, diagnosis, and cell delivery
AU2019311181A1 (en) 2018-07-27 2021-02-18 Research Development Foundation Chimeric immunogenic polypeptides
PH12022550081A1 (en) 2019-07-12 2023-04-12 Res Found Dev Ehrlichia vaccines and immunogenic compositions
US12226468B2 (en) 2023-06-26 2025-02-18 Research Development Foundation Immunoreactive peptides

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355777B1 (en) * 2000-04-28 2002-03-12 Research Development Foundation P43 antigen for the immunodiagnosis of canine ehrlichiosis and uses thereof
EP3527582B1 (en) * 2005-04-04 2022-08-17 IDEXX Laboratories, Inc. Ehrlichia canis diva (differentiate infected from vaccinated animals)
EP2064231B2 (en) * 2006-08-31 2020-08-26 Research Development Foundation Immunoreactive glycoprotein gp19 of ehrlichia canis

Also Published As

Publication number Publication date
US9605032B2 (en) 2017-03-28
AU2007348944B2 (en) 2013-01-10
JP2010502187A (ja) 2010-01-28
EP2064231A1 (en) 2009-06-03
WO2008112007A1 (en) 2008-09-18
CA2662246C (en) 2016-07-05
ES2397548T3 (es) 2013-03-07
EP2064231B2 (en) 2020-08-26
CA2662246A1 (en) 2008-09-18
JP5498164B2 (ja) 2014-05-21
US9814768B2 (en) 2017-11-14
US20100330091A1 (en) 2010-12-30
JP2014113149A (ja) 2014-06-26
US20150338406A1 (en) 2015-11-26
AU2007348944A1 (en) 2008-09-18
US9605033B2 (en) 2017-03-28
EP2064231B1 (en) 2012-10-24
JP5837917B2 (ja) 2015-12-24
US20170173136A1 (en) 2017-06-22

Similar Documents

Publication Publication Date Title
US11459379B2 (en) Immunoreactive protein orthologs of Ehrlichia canis and E. chaffeensis
ES2397548T3 (es) Glicoproteína inmunorreactiva gp19 de Ehrlichia canis
US10131705B2 (en) Vaccines and diagnostics for the ehrlichioses
WO2021195326A1 (en) Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)